Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Ben Yerxa
AddedMar 31, 2024
UpdatedMay 31, 2026
Ben Yerxa

Ben Yerxa

CEO, Foundation Fighting Blindness

CrunchbaseLinkedIn

Ben Yerxa's Career

Foundation Fighting Blindness
Foundation Fighting Blindness

Columbia, MD, US

CEO· C-Suite · Management
North Carolina Biotechnology Center
North Carolina Biotechnology Center

Triangle (historical), NC, US

Board Member· Board
Clearside Biomedical
Clearside Biomedical

Alpharetta, GA, US

Board Member· Board
Opus Genetics
Opus Genetics

Raleigh, NC, US

Co-Founder & CEO· C-Suite · Management
Nacuity Pharmaceuticals
Nacuity Pharmaceuticals

Fort Worth, TX, US

Board Member· Board
Envisia Therapeutics
Envisia Therapeutics

Morrisville, NC, US

Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Ben Yerxa's Career

Foundation Fighting Blindness
Foundation Fighting Blindness
NonprofitNonprofit$114M981971Columbia, MD, US
CEO· C-Suite · Management

Leadership at Foundation Fighting Blindness

Maryrose SylvesterMaryrose SylvesterBoard Member
Alan LandisAlan LandisFounder
Scott BurtScott BurtBoard Member
Aryeh BourkoffAryeh BourkoffBoard Member
Gil KlimanGil KlimanBoard Member
David BrintDavid BrintBoard Member
North Carolina Biotechnology Center
North Carolina Biotechnology Center
Series B$30.4M1161984Triangle (historical), NC, US
Board Member· Board

Leadership at North Carolina Biotechnology Center

James HuntJames HuntFounder
Art PappasArt PappasBoard Member
Doug EdgetonDoug EdgetonCEO
Clearside Biomedical
Clearside Biomedical
Public$188.9M362011Alpharetta, GA, US
Board Member· Board

Leadership at Clearside Biomedical

Mark PrausnitzMark PrausnitzCo-Founder
Christy ShafferChristy ShafferBoard Member
Bill HumphriesBill HumphriesBoard Member
Henry F EdelhauserHenry F EdelhauserCo-Founder
Jeffrey L. EdwardsJeffrey L. EdwardsBoard Member
George LasezkayGeorge LasezkayCEO
Opus Genetics
Opus Genetics
Seed$19M232004Raleigh, NC, US
Co-Founder & CEO· C-Suite · Management

Leadership at Opus Genetics

Jason MenzoJason MenzoCo-Founder
Peter GinsbergPeter GinsbergCo-Founder
Rusty KelleyRusty KelleyBoard Member
Jean BennettJean BennettBoard Member
Nacuity Pharmaceuticals
Nacuity Pharmaceuticals
Series B$18.5M302016Fort Worth, TX, US
Board Member· Board

Leadership at Nacuity Pharmaceuticals

Sanford HillsbergSanford HillsbergCo-Founder
Halden ConnerHalden ConnerCo-Founder
Isaac BlechIsaac BlechCo-Founder
David WohlbergDavid WohlbergCo-Founder

Similar to Nacuity Pharmaceuticals

EyeCyteEyeCyteLos Angeles, CA, USTherapeuticsest. 2005EyeCyteLos Angeles, CA, US · est. 2005

EyeCyte: Developing novel therapeutics for neovascular and degenerative retinal diseases.

Series A · $3M5
VisioxVisioxTarrytown, NY, USTherapeuticsest. 2022VisioxTarrytown, NY, US · est. 2022

Visiox: A privately-funded biopharmaceutical firm innovating new treatments for prevalent ophthalmic diseases.

Seed · $7M7
Nanoscope TherapeuticsNanoscope TherapeuticsBedford, TX, USGene Therapyest. 2017Nanoscope TherapeuticsBedford, TX, US · est. 2017

Nanoscope Therapeutics, a gene therapy company, uses light-sensitive molecules to treat retinal degenerative diseases and restore vision.

Seed · $3.5M28
Perfuse TherapeuticsPerfuse TherapeuticsSan Francisco, CA, USTherapeuticsest. 2018Perfuse TherapeuticsSan Francisco, CA, US · est. 2018

Perfuse Therapeutics: A seed-stage firm innovating retinal disease treatment, starting with glaucoma.

Series A · $9M11
Envisia Therapeutics
Envisia Therapeutics
Acquired$46.1M02013Morrisville, NC, US
Founder

Leadership at Envisia Therapeutics

Ed MathersEd MathersBoard Member
Adrienne GravesAdrienne GravesBoard Member
Gary M PhillipsGary M PhillipsBoard Member
William E YelleWilliam E YelleBoard Member
Steve BlochSteve BlochBoard Member

Similar to Envisia Therapeutics

VisioxVisioxTarrytown, NY, USTherapeuticsest. 2022VisioxTarrytown, NY, US · est. 2022

Visiox: A privately-funded biopharmaceutical firm innovating new treatments for prevalent ophthalmic diseases.

Seed · $7M7
EyeCyteEyeCyteLos Angeles, CA, USTherapeuticsest. 2005EyeCyteLos Angeles, CA, US · est. 2005

EyeCyte: Developing novel therapeutics for neovascular and degenerative retinal diseases.

Series A · $3M5
Imagen BiotechImagen BiotechNew York City, NY, USTherapeuticsest. 2011Imagen BiotechNew York City, NY, US · est. 2011

Imagen Biotech: Pioneering solutions for blinding diseases through innovative therapeutics.

Series A · $40M30
Nexis VisionNexis VisionMenlo Park, CA, USEye Solutionsest. 2007Nexis VisionMenlo Park, CA, US · est. 2007

Innovative biotech creating eye solutions for surgery and diseases.

Pre-Seed · $34.8M6

Ben Yerxa's Similar Executives & Operators

Bo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoBrian KimBrian KimCo-Founder · KakaoKim Beom-sooKim Beom-sooCo-Founder · KakaoJB LEEJB LEECo-Founder · Kakao

People Similar to Ben Yerxa

Christopher SchenkChristopher SchenkCo-Founder · Amma HealingRobert BenkowskiRobert BenkowskiFounder · Opsin BiotherapeuticsRachael NemethRachael NemethCo-Founder · OpusLuna YuLuna YuFounder · Genecis BioRob ChessRob ChessBoard Member · Caltech